IAP-based selective RIPK2 degrader
prolonged PD w/ 0.15 mpk SC Q3D dosing
E3 binder switch and property-based opt.
Commun. Biol., Mar. 20, 2020
GlaxoSmithKline, Stevenage, UK / PMCC
“PROTAC 6”
“PROTAC 6” (GlaxoSmithKline (GSK) IAP-based selective RIPK2 degrader with prolonged in vivo PD)